top of page
    • Nov 20, 2019
    • 1 min read

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with AbbVie on cancer drugs as well as autoimmune diseases — a new field for the upstart developer.




Comentários

bottom of page